MSCs Ameliorate Hepatic IR Injury by Modulating Phenotypic Transformation of Kupffer Cells Through Drp-1 Dependent Mitochondrial Dynamics

Shang, Longcheng; Wang, Man; Liu, Yang; Zhu, Xinhua; Wang, Shuai

doi:10.1007/s12015-023-10566-6

Cited by 7 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs inhibited mitochondrial fission in Kupffer cells, as evidenced by a decrease in the levels of Drp1 and Dnm2. The overexpression of Drp1 in the Kupffer cells promoted mitochondrial fission during IR injury and abolished MSC-regulated Kupffer cell M1/M2 polarization after IR injury, thereby antagonizing the therapeutic effect of MSCs [15]. Table 1 presents data on the effects exerted by MSCs or MSC derivatives on macrophages/Kupffer cells.…”

Section: Cell Therapy Of Nash Based On the Cross-talk Between Transpl...mentioning

confidence: 99%

See 1 more Smart Citation

Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis

Kholodenko,

Yarygin

2023

Biomedicines

View full text Add to dashboard Cite

Non-alcoholic steatohepatitis (NASH) is a serious public health issue associated with the obesity pandemic. Obesity is the main risk factor for the non-alcoholic fatty liver disease (NAFLD), which progresses to NASH and then to end-stage liver disease. Currently, there are no specific pharmacotherapies of NAFLD/NASH approved by the FDA or other national regulatory bodies and the treatment includes lifestyle adjustment and medicines for improving lipid metabolism, enhancing sensitivity to insulin, balancing oxidation, and counteracting fibrosis. Accordingly, further basic research and development of new therapeutic approaches are greatly needed. Mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles prevent induced hepatocyte death in vitro and attenuate NASH symptoms in animal models of the disease. They interact with hepatocytes directly, but also target other liver cells, including Kupffer cells and macrophages recruited from the blood flow. This review provides an update on the pathogenesis of NAFLD/NASH and the key role of macrophages in the development of the disease. We examine in detail the mechanisms of the cross-talk between the MSCs and the macrophages, which are likely to be among the key targets of MSCs and their derivatives in the course of NAFLD/NASH cell therapy.

show abstract

Section: Cell Therapy Of Nash Based On the Cross-talk Between Transpl...mentioning

confidence: 99%

“…The beneficial effects of the cell therapy of many diseases with MSCs are at least partly associated with immunomodulation via direct and indirect interactions with different immune cells [13], including macrophages [14]. The reactions of Kupffer cells, the liver macrophages, to MSC transplantation have also been reported [15].…”

Section: Introductionmentioning

confidence: 99%